Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor

Anticancer Research

Volumn 35, Issue 1, 2015, Pages 129-136

  Shindo, Yoshitaro ^a   Yoshimura, Kiyoshi ^a,b   Kuramasu, Atsuo ^a   Watanabe, Yusaku ^a   Ito, Hideaki ^a   Kondo, Tomoko ^a   Oga, Atsunori ^a   Ito, Hiroshi ^a   Yoshino, Shigefumi ^a   Hazama, Shoichi ^a   Tamada, Koji ^a   Yagita, Hideo ^c   Oka, Masaaki ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

4 1BB; Cancer immunotherapy; Immune checkpoint; PD 1

Indexed keywords

ANTINEOPLASTIC AGENT; CD137 ANTIGEN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4 1BB; MONOCLONAL ANTIBODY PD 1; PROGRAMMED DEATH 1 LIGAND 1; UNCLASSIFIED DRUG; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL INFILTRATION; CELL POPULATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; SUBCUTANEOUS TISSUE TUMOR; SUPPRESSOR CELL; TUMOR REJECTION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; DRUG POTENTIATION; DRUG SCREENING; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS, EXPERIMENTAL; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD137; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; IMMUNOTHERAPY; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES, REGULATORY;

EID: 84920448880     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Harris NL and Ronchese F: The role of B7 co-stimulation in Tcell immunity. Immunol Cell Biol 77: 304-311, 1999.
2. Topalian SL, Drake CG and Pardoll DM: Targeting the PD-1/B7- H1 (PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24: 207-212, 2012.
3. Pentcheva-Hoang T, Corse E and Allison JP: Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev 229: 67-87, 2009.
4. Fife BT, Guleria I, Gubbels Bupp M, Eagar TN, Tang Q, Bour- Jordan H, Yagita H, Azuma M, Sayegh MH, and Bluestone JA: Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med 203: 2737-2747, 2006.
5. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, and Sharpe AH: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-547, 1995.
6. Carreno BM and Collins M: The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 20: 29-53, 2002.
7. Blank C and Mackensen A: Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 56: 739-745, 2007.
8. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM and Sznol M: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454, 2012.
9. Wu YL, Liang J, Zhang W, Tanaka Y and Sugiyama H: Immunotherapies: the blockade of inhibitory signals. Int J Biol Sci 8: 1420-1430, 2012.
10. Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, Siadak AW, Brown TJ, Emswiler J, Raecho H, Larsen CP, Pearson TC, Ledbetter JA, Aruffo A and Mittler RS: 4-1BB costimulatory signals preferentially induce CD8+ T-cell proliferation and lead to the amplification in vivo of cytotoxic Tcell responses. J Exp Med 186: 47-55, 1997.
11. Wilcox RA, Tamada K, Strome SE and Chen L: Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T-cells and responsiveness to IL-2 but not cytolytic activity. J Immunol 169: 4230-4236, 2002.
12. Cannons JL, Lau P, Ghumman B, DeBenedette MA, Yagita H, Okumura K and Watts TH: 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T-cells with similar efficacy. J Immunol 167: 1313-1324, 2001.
13. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS and Chen L: Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 3: 682-685, 1997.
14. Taraban VY, Rowley TF, O'Brien L, Chan HT, Haswell LE, Green MH, Tutt AL, Glennie MJ and Al-Shamkhani A: Expression and co-stimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of antitumor immune responses. Eur J Immunol 32: 3617-3627, 2002.
15. Ascierto PA, Simeone E, Sznol M, Fu YX and Melero I: Clinical experiences with anti-CD137 and anti-PD-1 therapeutic antibodies. Semin Oncol 37: 508-516, 2010.
16. Corbett TH, Griswold DP Jr., Roberts BJ, Peckham JC and Schabel FM Jr.: Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 35: 2434-2439, 1975.
17. Aslakson CJ and Miller FR: Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52: 1399-1405, 1992.
18. Yoshimura K, Hazama S, Iizuka N, Yoshino S, Yamamoto K, Muraguchi M, Ohmoto Y, Noma T and Oka M: Successful immunogene therapy using colon cancer cells (colon 26) transfected with plasmid vector containing mature interleukin-18 cDNA and the Igkappa leader sequence. Cancer Gene Ther 8: 9-16, 2001.
19. Yamazaki T, Akiba H, Koyanagi A, Azuma M, Yagita H and Okumura K: Blockade of B7-H1 on macrophages suppresses CD4+ T-cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol 175: 1586-1592, 2005.
20. Yoshimura K, Laird LS, Chia CY, Meckel KF, Slansky JE, Thompson JM, Jain A, Pardoll DM and Schulick RD: Live attenuated Listeria monocytogenes effectively treats hepatic colorectal cancer metastases and is strongly enhanced by depletion of regulatory T-cells. Cancer Res 67: 10058-10066, 2007.
21. Huang AY, Gulden PH, Woods AS, Thomas MC, Tong CD, Wang W, Engelhard VH, Pasternack G, Cotter R, Hunt D, Pardoll DM and Jaffee EM: The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci USA 93: 9730-9735, 1996.
22. Maeda N, Yoshimura K, Yamamoto S, Kuramasu A, Inoue M, Suzuki N, Watanabe Y, Maeda Y, Kamei R, Tsunedomi R, Shindo Y, Inui M, Tamada K, Yoshino S, Hazama S and Oka M: Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T-cells, affects against recurrence-free survival in breast cancer patients. Ann Surg Oncol 2014.
23. Cho Y, Miyamoto M, Kato K, Fukunaga A, Shichinohe T, Kawarada Y, Hida Y, Oshikiri T, Kurokawa T, Suzuoki M, Nakakubo Y, Hiraoka K, Murakami S, Shinohara T, Itoh T, Okushiba S, Kondo S and Katoh H: CD4+ and CD8+ T-cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 63: 1555-1559, 2003.
24. Berghuis D, Santos SJ, Baelde HJ, Taminiau AH, Egeler RM, Schilham MW, Hogendoorn PC and Lankester AC: Proinflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) Tlymphocyte infiltration and affect tumour progression. J Pathol 223: 347-357, 2011.
25. Lee CS, Cragg M, Glennie M and Johnson P: Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol 76: 233-247, 2013.
26. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP and Ribas A: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369: 134-144, 2013.
27. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK and Sharpe AH: PD-L1 regulates the development, maintenance, and function of induced regulatory T-cells. J Exp Med 206: 3015-3029, 2009.
28. Pardoll D and Drake C: Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med 209: 201-209, 2012.